Estrogen regulation of apoptosis: How can one hormone stimulate and inhibit?

Breast Cancer Research

Volumn 11, Issue 3, 2009, Pages

  Lewis Wambi, Joan S ^a   Jordan, V Craig ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; DIETHYLSTILBESTROL DERIVATIVE; ESTRADIOL; ESTROGEN; ESTROGEN DERIVATIVE; FAS ANTIGEN; FAS LIGAND; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; METHYLTRIPHENYLETHYLENE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; RALOXIFENE; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN; TRIPHENYLCHLORETHYLENE; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR;

APOPTOSIS; BONE REMODELING; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CONTROL; CELL LINEAGE; CELL SURVIVAL; DRUG MEGADOSE; ESTROGEN RESPONSIVE ELEMENT; ESTROGEN THERAPY; HORMONAL REGULATION; HORMONE INHIBITION; HORMONE SENSITIVITY; HUMAN; LOW DRUG DOSE; MITOCHONDRION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR REGRESSION; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGENS; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 74049104166     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2255     Document Type: Review

References (89)

1. Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998, 3:49-61. 10.1023/A:1018770218022, 10819504.
2. Beatson CT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2:101-111.
3. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427. 10.1016/S0140-6736(03)14596-5, 12927427.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, . Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397, Writing Group for the Women's Health Initiative Investigators.
5. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351:1451-1467. 10.1016/S0140-6736(97)11423-4, 9605801.
6. Iwase H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 2008, 15:278-290. 10.1007/s12282-008-0071-y, 18810576.
7. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996, 12:2315-2324.
8. Foster JS, Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 1996, 10:488-498. 10.1210/me.10.5.488, 8732680.
9. Pietras RJ, Marquez-Garban DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 2007, 13:4672-4676. 10.1158/1078-0432.CCR-07-1373, 17699844.
10. Moriarty K, Kim KH, Bender JR. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006, 147:5557-5563. 10.1210/en.2006-0729, 16946015.
11. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006, 20:1996-2009. 10.1210/me.2005-0525, 16645038.
12. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003, 17:818-830. 10.1210/me.2002-0330, 12554767.
13. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008, 29:217-233. 2528847, 18216219, 10.1210/er.2006-0045.
14. Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M, Rostene W. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000, 65:593-598. 10.1016/S0039-128X(00)00172-0, 11108864.
15. Jordan VC. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer - survival or death?. J Clin Oncol 2008, 26:3073-3082. 10.1200/JCO.2008.17.5190, 18519949.
16. Jordan VC, Lewis JS, Osipo C, Cheng D. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast 2005, 14:624-630. 10.1016/j.breast.2005.08.022, 16202599.
17. Lewis JS, Cheng D, Jordan VC. Targeting oestrogen to kill the cancer but not the patient. Br J Cancer 2004, 90:944-949. 10.1038/sj.bjc.6601627, 14997187.
18. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005, 97:1746-1759.
19. Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001, 79:115-125. 10.1016/S0960-0760(01)00151-0, 11850215.
20. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001, 93:1714-1723. 10.1093/jnci/93.22.1714, 11717332.
21. Swaby RF, Jordan VC. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer 2008, 8:124-133. 10.3816/CBC.2008.n.012, 18621608.
22. Wolf DM, Jordan VC. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 1993, 127:23-33.
23. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000, 6:2028-2036.
24. Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim CS, Fine RL. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996, 88:908-917. 10.1093/jnci/88.13.908, 8656443.
25. Nilsen J, Mor G, Naftolin F. Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol 2000, 43:64-78. 10.1002/(SICI)1097-4695(200004)43:1<64::AID-NEU6>3.0.CO;2-7, 10756067.
26. Saintier D, Khanine V, Uzan B, Ea HK, de Vernejoul MC, Cohen-Solal ME. Estradiol inhibits adhesion and promotes apoptosis in murine osteoclasts in vitro. J Steroid Biochem Mol Biol 2006, 99:165-173. 10.1016/j.jsbmb.2006.01.009, 16621521.
27. Okasha SA, Ryu S, Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Evidence for estradiol-induced apoptosis and dysregulated T cell maturation in the thymus. Toxicology 2001, 163:49-62. 10.1016/S0300-483X(01)00374-2, 11376864.
28. Jiang SY, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591. 10.1093/jnci/84.8.580, 1556769.
29. Levenson AS, Jordan VC. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 1994, 51:229-239. 10.1016/0960-0760(94)90035-3, 7826884.
30. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981, 304:16-21.
31. Lewis JS, Osipo C, Meeke K, Jordan VC. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 2005, 94:131-141. 10.1016/j.jsbmb.2004.12.032, 15862958.
32. Song RX, Zhang Z, Mor G, Santen RJ. Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis 2005, 10:667-678. 10.1007/s10495-005-1903-2, 15909128.
33. Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 2008, 630:19-34. 2641021, 18637482.
34. Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC. Buthionine sulfoximine sensitizes anti-hormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Res 2008, 10:R104. 2656901, 19061505, 10.1186/bcr2208.
35. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003, 95:1597-1608.
36. Zhang Y, Zhao H, Asztalos S, Chisamore M, Sitabkhan Y, Tonetti DA. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res 2009, 7:498-510. 10.1158/1541-7786.MCR-08-0415, 19372579.
37. Haddow A, Watkinson JM, Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. BMJ 1944, 2:393-398.
38. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 1977, 237:2079-2078. 10.1001/jama.237.19.2079, 576887.
39. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971, 25:270-275.
40. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A. High-dose estrogen treatment in post-menopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001, 67:111-116. 10.1023/A:1010619225209, 11519859.
41. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999, 54:117-122. 10.1023/A:1006185805079, 10424402.
42. Ellis MJ, Dehdahti F, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Jeffe DB, Gao F, Fleming G, Silverman P, Dickler M, L C, Marcom PK. A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer [abstract]. Cancer Res 2009, 69:s67.
43. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003, 22:8543-8567. 10.1038/sj.onc.1207107, 14634618.
44. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
45. Ziegler DS, Kung AL. Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol 2008, 20:97-103. 10.1097/CCO.0b013e3282f310f6, 18043263.
46. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003, 10:26-35. 10.1038/sj.cdd.4401186, 12655293.
47. Tsujimoto Y. Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep 2002, 22:47-58. 10.1023/A:1016061006256, 12418550.
48. Talapatra S, Thompson CB. Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 2001, 298:873-878.
49. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003, 95:1586-1597.
50. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 2001, 7:3156-3165.
51. Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 2000, 83:782-791. 10.1054/bjoc.2000.1326, 10952784.
52. Mor G, Kohen F, Garcia-Velasco J, Nilsen J, Brown W, Song J, Naftolin F. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000, 73:185-194. 10.1016/S0960-0760(00)00081-9, 11070347.
53. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998, 1:543-551. 10.1016/S1097-2765(00)80054-4, 9660938.
54. Kavurma MM, Santiago FS, Bonfoco E, Khachigian LM. Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem 2001, 276:4964-4971. 10.1074/jbc.M009251200, 11053446.
55. Krishnan V, Wang X, Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 1994, 269:15912-15917.
56. Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 1997, 11:1569-1580. 10.1210/me.11.11.1569, 9328340.
57. Duan R, Porter W, Safe S. Estrogen-induced c-fos protoonco-gene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 1998, 139:1981-1990. 10.1210/en.139.4.1981, 9528985.
58. Sun G, Porter W, Safe S. Estrogen-induced retinoic acid receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complex. Mol Endocrinol 1998, 12:882-890. 10.1210/me.12.6.882, 9626663.
59. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 2000, 275:5379-5387. 10.1074/jbc.275.8.5379, 10681512.
60. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009, 15:1126-1132. 10.1158/1078-0432.CCR-08-0144, 19228717.
61. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007, 25:1114-1120. 10.1200/JCO.2006.07.1191, 17296974.
62. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991, 254:274-277. 10.1126/science.1833819, 1833819.
63. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241. 10.1016/S0092-8674(00)80405-5, 9346240.
64. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687-689. 10.1126/science.278.5338.687, 9381178.
65. John S, Nayvelt I, Hsu HC, Yang P, Liu W, Das GM, Thomas T, Thomas TJ. Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res 2008, 68:7855-7863. 10.1158/0008-5472.CAN-07-5875, 18829541.
66. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526. 10.1038/onc.2008.246, 18794885.
67. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260. 10.1146/annurev.immunol.16.1.225, 9597130.
68. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006, 25:6800-6816. 10.1038/sj.onc.1209938, 17072329.
69. Stoffel A, Levine AJ. Activation of NF-kappaB by the API2/MALT1 fusions inhibits p53 dependant but not FAS induced apoptosis: a directional link between NF-kappaB and p53. Cell Cycle 2004, 3:1017-1020.
70. Krasil'nikov MA, Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA. NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis. Mol Cell Biochem 2009, 324:65-71. 10.1007/s11010-008-9985-0, 19096761.
71. Voehringer DW. BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med 1999, 27:945-950. 10.1016/S0891-5849(99)00174-4, 10569627.
72. Ellerby LM, Ellerby HM, Park SM, Holleran AL, Murphy AN, Fiskum G, Kane DJ, Testa MP, Kayalar C, Bredesen DE. Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. J Neurochem 1996, 67:1259-1267.
73. Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res 1999, 246:183-192. 10.1006/excr.1998.4303, 9882527.
74. Schroder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC, Ozols RF. Glutathione and drug resistance. Cancer Invest 1996, 14:158-168. 10.3109/07357909609018891, 8597901.
75. Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK. Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer 2000, 89:1440-1447. 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.0.CO;2-0, 11013356.
76. Bailey HH. L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 1998, 111-112:239-254.
77. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 1994, 12:194-205.
78. Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997, 89:1789-1796. 10.1093/jnci/89.23.1789, 9392620.
79. Vasilevskaya I, O'Dwyer PJ. Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat 2003, 6:147-156. 10.1016/S1368-7646(03)00043-8, 12860462.
80. Altiok N, Koyuturk M, Altiok S. JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells. Breast Cancer Res Treat 2007, 105:247-254. 10.1007/s10549-006-9451-1, 17187235.
81. Park J, Kim I, Oh YJ, Lee K, Han PL, Choi EJ. Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-2. J Biol Chem 1997, 272:16725-16728. 10.1074/jbc.272.27.16725, 9201973.
82. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279-302. 10.1210/er.23.3.279, 12050121.
83. Teitelbaum SL. Osteoclasts: what do they do and how do they do it?. Am J Pathol 2007, 170:427-435. 1851862, 17255310, 10.2353/ajpath.2007.060834.
84. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R, . Mulitple Outcomes of Raloxifene Evaluation Investigators Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002, 87:3609-3617. 10.1210/jc.87.8.3609, 12161484, Mulitple Outcomes of Raloxifene Evaluation Investigators.
85. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 2001, 276:8836-8840. 10.1074/jbc.M010764200, 11121427.
86. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007, 130:811-823. 10.1016/j.cell.2007.07.025, 17803905.
87. Zeitlin BD, Zeitlin IJ, Nor JE. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 2008, 26:4180-4188. 10.1200/JCO.2007.15.7693, 18757333.
88. Stein CA, Benimetskaya L, Mani S. Antisense strategies for oncogene inactivation. Semin Oncol 2005, 32:563-572. 10.1053/j.seminoncol.2005.09.003, 16338422.
89. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 2003, 63:8118-8121.